Biologics Drug Discovery Market to Grow with a CAGR of 7.89% Globally through 2029

Rising research and development is expected to drive the Global Biologics Drug Discovery Market in the forecast period, 2025-2029.

According to TechSci Research report, “Biologics Drug Discovery Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Biologics Drug Discovery Market stood at USD 8.23 Billion in 2023 and is anticipated to grow with a CAGR of 7.89% through 2029. The Global Biologics Drug Discovery Market is undergoing a transformative phase within the pharmaceutical sector, characterized by a notable shift towards the development of biologics—therapeutic drugs sourced from living organisms. Biologics, encompassing monoclonal antibodies, vaccines, and gene therapies, present precise and cutting-edge treatment modalities for diverse diseases, thereby propelling the growth of the drug discovery market. Factors such as the rising incidence of chronic illnesses, advancements in biotechnology, and a deeper comprehension of molecular biology collectively contribute to the upsurge in biologics research. The persistent quest for novel and more efficacious treatments drives the demand for innovative drug discovery methodologies.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Biologics Drug Discovery Market”

The Global Biologics Drug Discovery Market is segmented into type, method, manufacture type, regional distribution, and company.

Based on manufacture type, in-house emerged as the dominant segment in Global Biologics Drug Discovery Market in 2023. Pharmaceutical firms often prioritize internal drug discovery efforts to safeguard their intellectual property. By conducting research and development in-house, companies can protect their proprietary technologies, compounds, and processes, thereby minimizing the risk of intellectual property theft or infringement. This approach also allows companies to allocate resources in line with their strategic priorities and specific research objectives. By directing investments towards areas with the greatest potential for success, firms can align their research efforts with long-term business goals. In-house drug discovery provides companies with greater control over the research and development process, enabling them to adapt swiftly to evolving market dynamics and scientific advancements. This flexibility facilitates accelerated decision-making, streamlined development timelines, and prompt responses to emerging opportunities or challenges. Moreover, internal drug discovery initiatives represent a substantial long-term investment in a company's research and development capabilities. By cultivating internal expertise and infrastructure, pharmaceutical companies can bolster their competitive standing, enrich their pipeline of innovative biologics, and ensure sustained growth over time.

Based on region, Europe has demonstrated significant growth in the global market of biologics drug discovery during the forecast period. Europe possesses a thriving biotechnology ecosystem, characterized by a multitude of academic research institutions, burgeoning biotech startups, and established pharmaceutical enterprises deeply involved in drug discovery and development. This collaborative atmosphere cultivates innovation and propels progress in biologics research, thus bolstering the region's expansion in the market. European governments play a pivotal role by offering substantial support and funding for biomedical research and innovation endeavors. Flagship programs like Horizon Europe, the European Union's premier research and innovation framework initiative, allocate significant resources to propel biotechnology and pharmaceutical research initiatives forward. This financial backing stimulates investment in biologics drug discovery and expedites the creation of groundbreaking therapies. Europe maintains a comprehensive regulatory framework for approving biologics and other pharmaceutical products. Regulatory bodies such as the European Medicines Agency (EMA) meticulously evaluate the safety, efficacy, and quality of biologic therapies. This transparent and consistent regulatory environment instills confidence in companies navigating the drug development process, facilitating the introduction of new biologics to the market.

Major companies operating in Global Biologics Drug Discovery Market are:

• AbbVie, Inc.
• Astellas Pharma, Inc.  
• AstraZeneca PLC 
• Bayer AG
• Bicon Ltd.
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd. 
• Gilead Sciences, Inc.
• Catalent, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Global Biologics Drug Discovery Market is driven by a rising need for precise and targeted therapies, spurred by the growing prevalence of chronic diseases. Heightened investments in research and development, particularly within the biologics domain, fuel innovation. Collaborations among pharmaceutical companies, academic institutions, and biotech enterprises promote synergies. Regulatory backing adjusts to accommodate the distinctive attributes of biologics, simplifying their development processes. The global shift towards personalized medicine further intensifies the demand for biologics, signaling a transformative era in healthcare marked by a concentration on effectiveness, safety, and tailored patient treatments”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Biologics Drug Discovery Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Monoclonal Antibodies, Recombinant Proteins, Others), By Method (Target Identification/ validation, Hit Generation/ Validation, Lead Identification, Lead Optimization), By Manufacture Type (In-House, Outsourced), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Biologics Drug Discovery Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Biologics Drug Discovery Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com